Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms

Cancer Prev Res (Phila). 2011 Apr;4(4):512-3. doi: 10.1158/1940-6207.CAPR-10-0373.

Abstract

Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Adenocarcinoma, Mucinous / drug therapy*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Pancreatic Ductal / drug therapy*
  • Erlotinib Hydrochloride
  • Humans
  • Male
  • Middle Aged
  • Mucin 5AC / biosynthesis
  • Mucin 5AC / drug effects
  • Pancreatic Neoplasms / drug therapy*
  • Quinazolines / pharmacokinetics
  • Quinazolines / therapeutic use*

Substances

  • Antineoplastic Agents
  • MUC5AC protein, human
  • Mucin 5AC
  • Quinazolines
  • Erlotinib Hydrochloride